Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Lancet Respir Med. 2023 Jun 19;11(9):791–803. doi: 10.1016/S2213-2600(23)00147-9

Figure 2.

Figure 2.

Kaplan-Meier estimates of cumulative mortality through Day 180 for the aviptadil group and the placebo group. Hazards ratio (HR) estimated with a proportional hazards regression model stratified by disease severity at entry. A HR > 1.0 favors placebo. Estimated for all 461 in the mITT cohort.